BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37121981)

  • 21. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
    Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
    Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRE-ABLATION THYROGLOBULIN AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER.
    Livhits MJ; Pasternak JD; Xiong M; Li N; Gosnell JE; Yeh MW; Chiu HK
    Endocr Pract; 2016 Nov; 22(11):1259-1266. PubMed ID: 27482611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
    Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
    Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Chami L; Travagli JP; Hartl D; Lumbroso J; Chougnet C; Lacroix L; Baudin E; Schlumberger M; Leboulleux S
    Endocr Relat Cancer; 2011 Apr; 18(2):R29-40. PubMed ID: 21183629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
    Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
    Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients.
    Campennì A; Giovanella L; Pignata SA; Vento A; Alibrandi A; Sturiale L; Laudicella R; Comis AD; Filice R; Giuffrida G; Stipo ME; Giovinazzo S; Trimarchi F; Ruggeri RM; Baldari S
    Oncotarget; 2018 Apr; 9(25):17491-17500. PubMed ID: 29707123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the efficacy of thyroglobulin and thyroglobulin/ thyroid-stimulating hormone ratio models in predicting a successful response to radioactive iodine therapy.
    Ju Y; Wang L; Cheng F; Huang F; Chen X; Song Q; Xiao J; Zhu X; Jia H
    BMC Endocr Disord; 2023 Jan; 23(1):19. PubMed ID: 36670396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin.
    Montella L; Caraglia M; Abbruzzese A; Soricelli A; Prete SD; Squame G; Salvatore M
    Exp Mol Med; 2004 Jun; 36(3):268-73. PubMed ID: 15272239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
    Lind P; Igerc I; Kohlfürst S
    Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma.
    Wang C; Zhang R; Wang R; Meng Z; Zhang G; Dong F; He Y; Tan J
    Front Endocrinol (Lausanne); 2021; 12():667544. PubMed ID: 34040584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.
    Roelants V; Nayer PD; Bouckaert A; Beckers C
    Eur J Nucl Med; 1997 Jul; 24(7):722-7. PubMed ID: 9211756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Data on repeated (131)I-WB scans and the incidence of positive Tg and negative (131)I-WBS in DTC patients from a 24 months study.
    Adedapo KS; Vangu MD
    Hell J Nucl Med; 2011; 14(2):131-4. PubMed ID: 21761014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
    Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
    Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of iodine-123 whole-body scan in planning iodine-131 treatment of the differentiated thyroid carcinoma in children and adolescence.
    Villani MF; Grossi A; Cassano B; Pizzoferro M; Ubertini G; Longo M; Garganese MC
    Nucl Med Commun; 2018 Dec; 39(12):1121-1128. PubMed ID: 30260898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
    Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
    Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
    [No Abstract]   [Full Text] [Related]  

  • 40. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance.
    Fatourechi V; Hay ID
    Semin Nucl Med; 2000 Apr; 30(2):107-14. PubMed ID: 10787191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.